Banna Virus Detected by Reverse Transcription-Loop-Mediated Isothermal Amplification
By LabMedica International staff writers Posted on 25 Dec 2018 |
Image: Visual detection of RT-LAMP assay. The tubes represent BAV strains and the negative controls used in the visual inspection. 1-7, BAV strains; 8-13, other viruses; 14, negative control (Photo courtesy of Wuhan Institute of Virology).
Banna virus (BAV) has been isolated from a diverse group of vertebrates and invertebrates, including mosquitos, ticks, midges, cattle, and pigs from different regions in China, Vietnam, and Indonesia. BAV is considered to be an emerging pathogen that can result in human infections with possible manifestation of fever and viral encephalitis.
Reverse transcription-loop mediated isothermal amplification (RT-LAMP) is a nucleic acid amplification approach that amplifies reverse transcribed DNA from RNA using strand displacement DNA polymerase under isothermal conditions. Due to its rapidness, simplicity, sensitivity and specificity, RT-LAMP has been successfully applied in the detection of various RNA viruses.
Scientists at the Wuhan Institute of Virology (Wuhan, China) designed a set of six specific primers to target the segment 12 of BAV, and the reverse transcription-loop mediated isothermal amplification (RT-LAMP) assay was developed and compared with conventional reverse transcription polymerase chain reaction (RT-PCR) method. The team used various cells and spiked samples to test the RT-LAMP method.
In running the RT-LAMP assay, a DEAOU RNA Amplification Kit (RT-LAMP) was used. One step RT-PCR amplification for BAV was performed using Prime Script One Step RT-PCR Kit Ver.2. RNA was extracted from 140 μL of BAV-infected C6/36 cell culture supernatant, BAV-spiked human serum or filtered mosquito homogenate samples using the QIAamp Viral RNA Mini Kit.
The team reported that the amplification of the RT-LAMP assay can be obtained within 40 minutes at 65 °C. The results from specificity showed that only target BAVs RNA including genotypes A, B and C were amplified and the assay demonstrated a sensitivity of 3.6 × 10−2 PFU/mL, which was higher than conventional RT-PCR measurement. A good reliability for the assay was presented in the further evaluation for BAVs RNA from serial diluted BAV-spiked serum and 47 pools of field mosquito samples.
The authors concluded that they had successfully developed a RT-LAMP assay for the detection of BAV, which provides a potential new molecular diagnostic test for BAV that could be applied in the field or clinic in the future, and that may contribute to the preparedness for future outbreaks of a BAV endemic, especially for regions with limited resources available. The study was published online on November 2, 2018, in the International Journal of Infectious Diseases.
Related Links:
Wuhan Institute of Virology
Reverse transcription-loop mediated isothermal amplification (RT-LAMP) is a nucleic acid amplification approach that amplifies reverse transcribed DNA from RNA using strand displacement DNA polymerase under isothermal conditions. Due to its rapidness, simplicity, sensitivity and specificity, RT-LAMP has been successfully applied in the detection of various RNA viruses.
Scientists at the Wuhan Institute of Virology (Wuhan, China) designed a set of six specific primers to target the segment 12 of BAV, and the reverse transcription-loop mediated isothermal amplification (RT-LAMP) assay was developed and compared with conventional reverse transcription polymerase chain reaction (RT-PCR) method. The team used various cells and spiked samples to test the RT-LAMP method.
In running the RT-LAMP assay, a DEAOU RNA Amplification Kit (RT-LAMP) was used. One step RT-PCR amplification for BAV was performed using Prime Script One Step RT-PCR Kit Ver.2. RNA was extracted from 140 μL of BAV-infected C6/36 cell culture supernatant, BAV-spiked human serum or filtered mosquito homogenate samples using the QIAamp Viral RNA Mini Kit.
The team reported that the amplification of the RT-LAMP assay can be obtained within 40 minutes at 65 °C. The results from specificity showed that only target BAVs RNA including genotypes A, B and C were amplified and the assay demonstrated a sensitivity of 3.6 × 10−2 PFU/mL, which was higher than conventional RT-PCR measurement. A good reliability for the assay was presented in the further evaluation for BAVs RNA from serial diluted BAV-spiked serum and 47 pools of field mosquito samples.
The authors concluded that they had successfully developed a RT-LAMP assay for the detection of BAV, which provides a potential new molecular diagnostic test for BAV that could be applied in the field or clinic in the future, and that may contribute to the preparedness for future outbreaks of a BAV endemic, especially for regions with limited resources available. The study was published online on November 2, 2018, in the International Journal of Infectious Diseases.
Related Links:
Wuhan Institute of Virology
Latest Molecular Diagnostics News
- Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans
- Unique Autoantibody Signature to Help Diagnose Multiple Sclerosis Years before Symptom Onset
- Blood Test Could Detect HPV-Associated Cancers 10 Years before Clinical Diagnosis
- Low-Cost Point-Of-Care Diagnostic to Expand Access to STI Testing
- 18-Gene Urine Test for Prostate Cancer to Help Avoid Unnecessary Biopsies
- Urine-Based Test Detects Head and Neck Cancer
- Blood-Based Test Detects and Monitors Aggressive Small Cell Lung Cancer
- Blood-Based Machine Learning Assay Noninvasively Detects Ovarian Cancer
- Simple PCR Assay Accurately Differentiates Between Small Cell Lung Cancer Subtypes
- Revolutionary T-Cell Analysis Approach Enables Cancer Early Detection
- Single Genetic Test to Accelerate Diagnoses for Rare Developmental Disorders
- Upgraded Syndromic Testing Analyzer Enables Remote Test Results Access
- Respiratory and Throat Infection PCR Test Detects Multiple Pathogens with Overlapping Symptoms
- Blood Circulating Nucleic Acid Enrichment Technique Enables Non-Invasive Liver Cancer Diagnosis
- First FDA-Approved Molecular Test to Screen Blood Donors for Malaria Could Improve Patient Safety
- Fluid Biomarker Test Detects Neurodegenerative Diseases Before Symptoms Appear